Associate Professor Kerrie McDonald

Nalkiran HS; McDonald KL, 2017, 'Is neuroglial antigen 2 a potential contributor to cilengitide response in glioblastoma?', Journal of Cancer Research and Therapeutics, vol. 13, pp. 329 - 336, http://dx.doi.org/10.4103/0973-1482.188438

Lu VM; McDonald KL, 2017, 'The current evidence of statin use affecting glioblastoma prognosis', Journal of Clinical Neuroscience, vol. 42, pp. 196 - 197, http://dx.doi.org/10.1016/j.jocn.2017.04.036

Jue TR; Nozue K; Lester AJ; Joshi S; Schroder LBW; Whittaker SP; Nixdorf S; Rapkins RW; Khasraw M; McDonald KL, 2017, 'Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma', Journal of Translational Medicine, vol. 15, http://dx.doi.org/10.1186/s12967-017-1164-1

Sinnadurai M; McDonald KL, 2017, 'Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma', Journal of Neuro-Oncology, vol. 132, pp. 359 - 372, http://dx.doi.org/10.1007/s11060-017-2390-3

Hau E; Shen H; Clark C; Graham PH; Koh ES; L Mcdonald K, 2016, 'The evolving roles and controversies of radiotherapy in the treatment of glioblastoma', Journal of Medical Radiation Sciences, http://dx.doi.org/10.1002/jmrs.149

Jue TR; McDonald KL, 2016, 'The challenges associated with molecular targeted therapies for glioblastoma', Journal of Neuro-Oncology, vol. 127, pp. 427 - 434, http://dx.doi.org/10.1007/s11060-016-2080-6

Rapkins RW; Wang F; Nguyen HTN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL, 2015, 'The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide', Neuro-Oncology, vol. 17, pp. 1589 - 1598, http://dx.doi.org/10.1093/neuonc/nov064

Schröder LBW; McDonald KL, 2015, 'CDK4/6 inhibitor PD0332991 in glioblastoma treatment: Does it have a future?', Frontiers in Oncology, vol. 5, http://dx.doi.org/10.3389/fonc.2015.00259

Shen H; Hau E; Joshi S; Dilda PJ; McDonald KL, 2015, 'Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism', Molecular Cancer Therapeutics, vol. 14, pp. 1794 - 1804, http://dx.doi.org/10.1158/1535-7163.MCT-15-0247

Mallawaaratchy DM; Buckland ME; McDonald KL; Li CCY; Ly L; Sykes EK; Christopherson RI; Kaufman KL, 2015, 'Membrane Proteome Analysis of Glioblastoma Cell Invasion', Journal of Neuropathology and Experimental Neurology, vol. 74, pp. 425 - 441, http://dx.doi.org/10.1097/NEN.0000000000000187

McDonald KL; Tabone T; Nowak AK; Erber WN, 2015, 'Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation', Oncology Letters, vol. 9, pp. 2063 - 2067, http://dx.doi.org/10.3892/ol.2015.2980

Shen H; Decollogne S; Dilda PJ; Hau E; Chung SA; Luk PP; Hogg PJ; McDonald KL, 2015, 'Dual-targeting of aberrant glucose metabolism in glioblastoma', Journal of Experimental and Clinical Cancer Research, vol. 34, http://dx.doi.org/10.1186/s13046-015-0130-0

Jue TR; Hovey E; Davis S; Carleton O; McDonald KL, 2014, 'Incorporation of biomarkers in phase II studies of recurrent glioblastoma', Tumor Biology, vol. 36, pp. 153 - 162, http://dx.doi.org/10.1007/s13277-014-2960-3

Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ, 2014, 'Involvement of the kynurenine pathway in human glioma pathophysiology.', PLoS One, vol. 9, pp. e112945, http://dx.doi.org/10.1371/journal.pone.0112945

Tivnan A; Zhao J; Johns TG; Day BW; Stringer BW; Boyd AW; Tiwari S; Giles KM; Teo C; McDonald KL, 2014, 'The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma', Tumor Biology, vol. 35, pp. 1459 - 1465, http://dx.doi.org/10.1007/s13277-013-1200-6

Tabone T; Erber WN; Abuhusain HJ; McDonald KL; Nowak AK, 2014, 'Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study', Journal of Clinical Pathology, http://dx.doi.org/10.1136/jclinpath-2014-202173

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, vol. 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Yeung YT; McDonald KL; Grewal T; Munoz L, 2013, 'Interleukins in glioblastoma pathophysiology: Implications for therapy', British Journal of Pharmacology, vol. 168, pp. 591 - 606, http://dx.doi.org/10.1111/bph.12008

McDonald KL; Aw G; Kleihues P, 2013, 'Role of biomarkers in the clinical management of glioblastomas: What are the barriers and how can we overcome them?', Frontiers in Neurology, vol. 3 JAN, http://dx.doi.org/10.3389/fneur.2012.00188

Tivnan A; McDonald KL, 2013, 'Current Progress for the Use of miRNAs in Glioblastoma Treatment', Molecular Neurobiology, pp. 1 - 12, http://dx.doi.org/10.1007/s12035-013-8464-0

Wong JWH; Abuhusain HJ; McDonald KL; Don AS, 2012, 'MMSAT: Automated quantification of metabolites in selected reaction monitoring experiments', Analytical Chemistry, vol. 84, pp. 470 - 474, http://dx.doi.org/10.1021/ac2026578

Yeung YT; Bryce NS; Adams S; Braidy N; Konayagi M; McDonald KL; Teo C; Guillemin GJ; Grewal T; Munoz L, 2012, 'P38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells', Journal of Neuro-Oncology, vol. 109, pp. 35 - 44, http://dx.doi.org/10.1007/s11060-012-0875-7

Chung SA; Dilda PJ; Ramsay EE; Teo C; Hogg PJ; McDonald KL, 2011, 'PENAO: A novel tumor metabolism inhibitor for glioblastoma', CANCER RESEARCH, vol. 71, http://dx.doi.org/10.1158/1538-7445.AM2011-2604

Sevim H; Parkinson JF; McDonald KL, 2011, 'Etoposide-mediated glioblastoma cell death: Dependent or independent on the expression of its target, topoisomerase II alpha?', Journal of Cancer Research and Clinical Oncology, vol. 137, pp. 1705 - 1712, http://dx.doi.org/10.1007/s00432-011-1046-5

Lu D; Mreich E; Chung S; Teo C; Wheeler H; McDonald KL, 2011, 'MGMT PROMOTER METHYLATION AND DNA MISMATCH REPAIR IN PRIMARY AND RELAPSED GLIOBLASTOMA', NEURO-ONCOLOGY, vol. 13, pp. 16 - 17, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Sevim H; Chung L; Wheeler HT; Baxter RC; McDonald KL, 2011, 'ABERRANT EXPRESSION OF LOW-MOLECULAR-WEIGHT PROTEINS ASSOCIATED WITH RESPONSE TO CONVENTIONAL CONCURRENT CHEMORADIOTHERAPY TREATMENT', NEURO-ONCOLOGY, vol. 13, pp. 79 - 80, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Abuhusain HJ; McDonald KL; Don AS, 2011, 'HIGH-THROUGHPUT LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MEASUREMENTS OF BIOACTIVE LIPIDS INTEGRATED WITH GENE EXPRESSION DATA IN GLIOBLASTOMA', NEURO-ONCOLOGY, vol. 13, pp. 81 - 81, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600328&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

McDonald KL, 2011, 'DRIVING A MOTOR VEHICLE AFTER DIAGNOSIS OF A BRAIN TUMOR: A PRIVILEGE, NOT A RIGHT', NEURO-ONCOLOGY, vol. 13, pp. 125 - 126, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297026600495&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Fowler A; Thomson D; Giles KM; Maleki S; Mreich E; Wheeler H; Leedman P; Biggs MT; Cook R; Little N, 2011, 'MiR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion', European Journal of Cancer, vol. 47, pp. 953 - 963, http://dx.doi.org/10.1016/j.ejca.2010.11.026

McDonald KL; McDonnell J; Muntoni A; Henson JD; Hegi ME; Von Deimling A; Wheeler HR; Cook RJ; Biggs MT; Little NS, 2010, 'Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival', Journal of Neuropathology and Experimental Neurology, vol. 69, pp. 729 - 736, http://dx.doi.org/10.1097/NEN.0b013e3181e576cf

Duncan CG; Killela PJ; Payne CA; Lampson B; Chen WC; Liu J; Solomon D; Waldman T; Towers AJ; Gregory SG, 2010, 'Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.', Oncotarget, vol. 1, pp. 265 - 277, http://dx.doi.org/10.18632/oncotarget.137

Elston MS; Gill AJ; Conaglen JV; Clarkson A; Cook RJ; Little NS; Robinson BG; Clifton-Bligh RJ; McDonald KL, 2009, 'Nuclear accumulation of E-Cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas', Journal of Clinical Endocrinology and Metabolism, vol. 94, pp. 1436 - 1442, http://dx.doi.org/10.1210/jc.2008-2075

McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB, 2009, 'Low O⁶-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours', Clinical Endocrinology, vol. 71, pp. 226 - 233, http://dx.doi.org/10.1111/j.1365-2265.2008.03487.x

Soon PSH; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB, 2009, 'Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas', Endocrine-Related Cancer, vol. 16, pp. 573 - 583, http://dx.doi.org/10.1677/ERC-08-0237

Elston MS; Gill AJ; Conaglen JV; Clarkson A; Shaw JM; Law AJJ; Cook RJ; Little NS; Clifton-Bligh RJ; Robinson BG, 2008, 'Wnt pathway inhibitors are strongly down-regulated in pituitary tumors', Endocrinology, vol. 149, pp. 1235 - 1242, http://dx.doi.org/10.1210/en.2007-0542

Payne CA; Maleki S; Messina M; O'Sullivan MG; Stone G; Hall NR; Parkinson JF; Wheeler HR; Cook RJ; Biggs MT, 2008, 'Loss of prostaglandin D2 synthase: A key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma', Molecular Cancer Therapeutics, vol. 7, pp. 3420 - 3428, http://dx.doi.org/10.1158/1535-7163.MCT-08-0629

Soon PSH; Libe R; Benn DE; Gill A; Shaw J; Sywak MS; Groussin L; Bertagna X; Gicquel C; Bertherat J, 2008, 'Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors', Annals of Surgery, vol. 247, pp. 157 - 164, http://dx.doi.org/10.1097/SLA.0b013e318153ff55

Soon PSH; McDonald KL; Robinson BG; Sidhu SB, 2008, 'Molecular markers and the pathogenesis of adrenocortical cancer', Oncologist, vol. 13, pp. 548 - 561, http://dx.doi.org/10.1634/theoncologist.2007-0243

McDonald KL; O'Sullivan MG; Parkinson JF; Shaw JM; Payne CA; Brewer JM; Young L; Reader DJ; Wheeler HT; Cook RJ, 2007, 'IQGAP1 and IGFBP2: Valuable biomarkers for determining prognosis in glioma patients', Journal of Neuropathology and Experimental Neurology, vol. 66, pp. 405 - 417, http://dx.doi.org/10.1097/nen.0b013e31804567d7

Mallawaaratchy DM; McDonald KL; Sykes EK; Buckland ME; Christopherson RI; Kaufman KL, 2014, 'NOVEL PROTEINS ASSOCIATED WITH INVADOPODIA STRUCTURES IN GLIOBLASTOMA MULTIFORME', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, Turin, ITALY, presented at 11th Congress of the European-Association-of-Neuro-Oncology, Turin, ITALY, 09 - 12 October 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344235700384&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ, 2014, 'Involvement of the kynurenine pathway in human glioma pathophysiology', in PLoS ONE, http://dx.doi.org/10.1371/journal.pone.0112945

Shen H; Luk PP; Chung SA; Decollogne S; Dilda PJ; Hogg PJ; McDonald KL, 2013, 'PENAO, a novel mitochondria-targeted agent, has shown potent antitumor effect on glioblastoma in vitro and in vivo', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-1701

Nozue-Okada K; Nagane M; McDonald KL, 2013, 'COMBINING PARP INHIBITORS WITH TMZ: IMPROVED EFFICACY OBSERVED IN RECURRENT PATIENT-DERIVED CELL LINES COMPARED TO PRIMARY CELLS', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, San Francisco, CA, pp. 54 - 54, presented at 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO), San Francisco, CA, 21 - 24 November 2013, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000327456200226&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a